Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H15N |
Molecular Weight | 149.2328 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(N)CC1=CC=CC=C1
InChI
InChIKey=DHHVAGZRUROJKS-UHFFFAOYSA-N
InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3
Molecular Formula | C10H15N |
Molecular Weight | 149.2328 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00191Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html
Sources: http://www.drugbank.ca/drugs/DB00191
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html
Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 Sources: http://www.drugbank.ca/drugs/DB00191 |
0.31 µM [EC50] | ||
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11911838 |
498.0 µM [Ki] | ||
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11911838 |
375.0 µM [Ki] | ||
Target ID: CHEMBL222 Sources: http://www.drugbank.ca/drugs/DB00191 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ADIPEX-P Approved UseADIPEX-P® is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
44.78 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
49.1 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2057.33 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2000 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.63 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
20 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82.5% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Other AEs: Abdominal pain, Dizziness... Other AEs: Abdominal pain (6%) Sources: Dizziness (6%) Early satiety (6%) Intermittent headache (6%) Nausea (6%) Swollen lips (6%) Upper respiratory infection (6%) |
37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Other AEs: Anorexia, Back pain... Other AEs: Anorexia (6%) Sources: Back pain (6%) Chapped lips (6%) Dry skin (6%) Dyspepsia (6%) Early satiety (6%) Irregular pulse (6%) Nausea (6%) |
390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years Health Status: healthy Age Group: mean age 30 years Sex: M+F Sources: |
Other AEs: Tachycardia, Hypertension... Other AEs: Tachycardia Sources: Hypertension Visual disorders NEC Nausea Insomnia Anxiety |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Disc. AE: Amnesia, Judgement impaired... Other AEs: Disorder sleep, Depression... AEs leading to discontinuation/dose reduction: Amnesia (0.3%) Other AEs:Judgement impaired (0.3%) Memory impairment (0.3%) Paraesthesia (0.3%) Depression (1%) Anxiety (0.3%) Vision blurred (0.3%) Eye pain (0.3%) Abdominal pain (0.3%) Tuberculosis skin test positive (0.3%) Nephrolithiasis (0.3%) Disorder sleep (12.9%) Sources: Depression (8.1%) Anxiety (9.5%) Cardiac arrhythmia (4.1%) Ischemic heart disease (1%) Disturbance in attention (3.1%) Memory impairment (2%) Cognitive disorders (1.4%) Language disorder (0.3%) Ocular disorders NEC (4.1%) Dyskinesias and movement disorders NEC (1.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Dizziness | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Early satiety | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Intermittent headache | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Nausea | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Swollen lips | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Upper respiratory infection | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Anorexia | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Back pain | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Chapped lips | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Dry skin | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Dyspepsia | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Early satiety | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Irregular pulse | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Nausea | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: |
healthy, 18 - 45 years old Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Sources: |
Anxiety | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years Health Status: healthy Age Group: mean age 30 years Sex: M+F Sources: |
|
Hypertension | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years Health Status: healthy Age Group: mean age 30 years Sex: M+F Sources: |
|
Insomnia | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years Health Status: healthy Age Group: mean age 30 years Sex: M+F Sources: |
|
Nausea | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years Health Status: healthy Age Group: mean age 30 years Sex: M+F Sources: |
|
Tachycardia | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years Health Status: healthy Age Group: mean age 30 years Sex: M+F Sources: |
|
Visual disorders NEC | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years Health Status: healthy Age Group: mean age 30 years Sex: M+F Sources: |
|
Language disorder | 0.3% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Abdominal pain | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Amnesia | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Anxiety | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Eye pain | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Judgement impaired | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Memory impairment | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Nephrolithiasis | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Paraesthesia | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Tuberculosis skin test positive | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Vision blurred | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Ischemic heart disease | 1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Depression | 1% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Cognitive disorders | 1.4% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Dyskinesias and movement disorders NEC | 1.4% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Disorder sleep | 12.9% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Memory impairment | 2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Disturbance in attention | 3.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Cardiac arrhythmia | 4.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Ocular disorders NEC | 4.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Depression | 8.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Anxiety | 9.5% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean age 51.9 years Health Status: unhealthy Age Group: mean age 51.9 years Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=17 Page: 17.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39,38 |
major | weak (co-administration study) Comment: In the presence of topiramate, phentermine Cmax and AUC0-inf increased 13 and 42%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39,38 |
PubMed
Title | Date | PubMed |
---|---|---|
[Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine]. | 1998 Dec 1 |
|
[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants]. | 1998 Dec 1 |
|
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramin. | 2000 Jun |
|
Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. | 2000 May 2 |
|
A concise review on the therapeutics of obesity. | 2000 Oct |
|
Appetite suppressants and valvular heart disease. | 2001 Apr |
|
Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. | 2001 Dec |
|
Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. | 2001 Jul |
|
Separation of sympathomimetic amines of abuse and related compounds by micellar electrokinetic chromatography. | 2001 Jul |
|
Pharmacologic options for the treatment of obesity. | 2001 Jul 15 |
|
Bitter pills, bad medicine. | 2001 Jun 4 |
|
A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule. | 2001 Mar 1 |
|
Fluorometric determination of DL-fenfluramine, DL-norfenfluramine and phentermine in plasma by achiral and chiral high-performance liquid chromatography. | 2001 Nov 5 |
|
Fenfluramine and phentermine. | 2001 Nov 6 |
|
Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. | 2001 Nov-Dec |
|
Herbal therapy for management of obesity: observations from a clinical endocrinology practice. | 2001 Nov-Dec |
|
Drug treatment of obesity. | 2001 Oct |
|
Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine. | 2001 Oct |
|
Operation for anorexigen-associated valvular heart disease. | 2001 Oct |
|
High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label. | 2001 Oct |
|
Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. | 2001 Oct 24-31 |
|
Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol. | 2001 Sep |
|
The relationship between health-related quality of life and weight loss. | 2001 Sep |
|
Pharmacotherapy of obesity: currently marketed and upcoming agents. | 2002 |
|
Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. | 2002 Jan-Feb |
|
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat. | 2003 Apr |
|
Effects of tyrosine, phentermine, caffeine D-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation. | 2003 Aug |
|
A comparison of tyrosine against placebo, phentermine, caffeine, and D-amphetamine during sleep deprivation. | 2003 Aug |
|
Obesity. | 2003 Dec |
|
Do these doctors give medicine a black eye? | 2003 Dec |
|
Ischemic colitis after weight-loss medication. | 2003 Dec |
|
The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. | 2003 Dec |
|
Internet pharmacy prescription and phentermine overdose. | 2003 Feb |
|
Medical monitoring for pharmaceutical injuries: tort law for the public's health? | 2003 Feb 19 |
|
Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. | 2003 Jul 5 |
|
Risk of valvular heart disease associated with use of fenfluramine. | 2003 Jun 11 |
|
National trends in antiobesity medication use. | 2003 May 12 |
|
Malpractice. Conviction upheld for doctor who treated AIDS with fen/phen. | 2003 May 9 |
|
Obesity: an overview on its current perspectives and treatment options. | 2004 Apr 14 |
|
The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment. | 2004 Dec |
|
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women. | 2004 Dec |
|
Going before disciplinary board without counsel is unwise. Case on point: Slone-Vasquez v. Kentucky Board Of Nursing, 2003 WL 22976179 S.W.3d-KY. | 2004 Jan |
|
Pharmacological and surgical treatment of obesity. | 2004 Jul |
|
Relationship between collagen fibrils, glycosaminoglycans, and stress relaxation in mitral valve chordae tendineae. | 2004 Jul |
|
Taking things to heart. | 2004 Jul |
|
Obesity. | 2004 Jun |
|
The long-term management of obesity with continuing pharmacotherapy. | 2004 Nov |
|
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. | 2005 Jan 25 |
|
Effects of phentermine and phenformin on biomarkers of aging in rats. | 2005 Jan-Feb |
|
Acute nonarteritic ischaemic optic neuropathy after phentermine. | 2005 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/phentermine.html
Usual Adult Dose for Weight Loss
15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Usual Pediatric Dose for Weight Loss
17 years or older:
15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10799660
Phentermine inhibited serotonin-metabolizing (MAO-A) activity in rat lung, brain, and liver with K(i) values of 85-88 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:36:25 GMT 2025
by
admin
on
Mon Mar 31 17:36:25 GMT 2025
|
Record UNII |
C045TQL4WP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175651
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
WHO-VATC |
QA08AA01
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
NDF-RT |
N0000175423
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
DEA NO. |
1640
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
NCI_THESAURUS |
C29728
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
WHO-ATC |
A08AA01
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
QSIVA (REFUSED: OBESITY)
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
LIVERTOX |
NBK548947
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
NDF-RT |
N0000175372
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
||
|
NDF-RT |
N0000175372
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
204-522-1
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
1064
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL1574
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
8080
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
m8644
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB09784MIG
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
3158
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
C61890
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
759163
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
PHENTERMINE
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
C045TQL4WP
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
4771
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
8152
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
C045TQL4WP
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
100000082243
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
DB00191
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
D010645
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
122-09-8
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
7269
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
2140
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY | |||
|
DTXSID9023461
Created by
admin on Mon Mar 31 17:36:25 GMT 2025 , Edited by admin on Mon Mar 31 17:36:25 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
SUB_CONCEPT->SUBSTANCE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||